

# A DETAILS REVIEW OF SEVERE ACUTE RESPIRATORY SYNDROME

**Dr..Gomathi M Assistant Professor<sup>1</sup>,**

**Dr.Jaikumar S Associate Professor<sup>2</sup>**

*Meenakshi Academy of Higher Education and Research*

*gomathim@mmchri.ac.in*

## **Abstract**

*The causative agent of coronavirus disease (COVID-19) has omnipresent worldwide spread, infecting more than two million people and causing over 150,000 deaths worldwide, resulting in devastating global health emergencies. Extreme acute respiratory syndrome 2 (sarkozydia) Early in its global expansion, the COVI-19 pandemic was further fuelled by insufficient access to laboratory research. Real-time RT-PCR Diagnostic Panel was the first test obtained from the US Food and Drug Administration on February 4, 2020, by the Centers for Disease Control and Prevention (CDC) 2019–Novel Coronavirus (2019–nCoV)<sup>1-3</sup>. This test was therefore introduced by a significant number of public health and clinical labs in the USA. Many manufacturers of commercial instruments then obtained EUAs for molecular SARS-CoV-2 identification. However, producers also assign reagents. Many of the clinical laboratories have therefore used several platforms to satisfy research criteria.*

**Keywords: SARS, PANDEMIC, COVID**

## **INTRODUCTION**

Coronavirus 2019 (COVID-19) was a potential cure for convalescent plasma, and a US Food and Drug Administration approval for hospitalised COVID-19 patients was issued. The plasma is an emergency treatment. We recently found that the early treatment of CIVC-19 patients with rehabilitation plasma containing high-titre anti spike protein receptor binding domain (RBD)IgG dramatically reduces mortality outcomes from an intermediate review of a propensity-associated research. The collection and transfusion of the maximum titer units available were facilitated in the prospective determination of enzyme-connected

immunosorbent assay IgG titer<sup>4-7</sup>. Retroactive research by Ortho VITROS IgG showed that the average signal/cuts ratio for transfused units was 24,0, a value well above the recently needed 12.0 cut-off to designate highly titrated plasma congestion. for the US Food and Drug Administration. With regard to changing mortality, our study showed that COVID-19 patients with strongly titrated convalescent plasma were transfused at an ideal window of 44 hours after hospitalisation. The study, in general, supports our preliminary findings that COVID-19 transfusions of patients with high-title RBD IgG anti-spike proteins found in convalescent plasmas decrease dramatically their mortality soon after hospitalisation, respectively<sup>8-11</sup>.

## **SARS 2 SPREAD**

Coronavirus 2019 (COVID-19), due to extreme acute coronavirus 2 syndrome, has spread quickly across the globe. This condition is caused by SARS-CoV-2. At the end of June 2020, over five million confirmed cases and over 500,000 deaths were registered (WHO, 2020). The epidemic's characteristics suggest that goutlets exhaled during near contact and fomites will transmit SARS-CoV-2 (WHO-China, 2020). Potential airborne propagation in health services is also envisaged because of such aerosol producing procedures<sup>12-15</sup>. After virus identification in stools, the function of the fecal–oral pathway in indoor environments is still determined. The relative importance of fomite delivery, close communication, and the alleged fecal-oral path remains, however, important. There has also been major contamination in hospitals. According to the China CDC Weekly 2020, of a 44,672 COVID-19 cases reported in China by 11 February 2020, there were 1716 cases of health care staff infected by the Novel Coronavirus Pneumonia Emergency Response Epidemiology Unit, in 2020. In order to protect healthcare staff, it is important to consider the risk of infection in hospital settings<sup>16-18</sup>.

## **INDETIFICATION OF INFECTION**

There are a variety of methods for assessing and recognising the present or previous infection and status of a coronavirus (COVID-19) infection, including the extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The recommended primary form of screening is the RT-PCR, with upper respiratory samples by nasopharyngeal or oropharyngeal swabs. In samples of non-pregnant females, the technique was shown to be extremely specific (95%) and adaptive (70%). The PCR-RT can detect viral materials present or past, while serological experiments measure the development of SARS-CoV-2 antibodies and can help indicate an

existing infection. The serum immunoglobulin (Ig) M (IgM), IgG, and IgA serum antibody studies are focused on the demonstration of such human serum anticorps as SARS-Co-V-2 diagnostic methods. In the blood samples of patients with positive RT-PCR 2-12 days after symptoms and according to sociodemographic conditions, these antibodies can be shown<sup>19-24</sup>.

## DISCUSSION

The positive SARS-COV-2 screening with the RT-PCR tests is 86–88 percent for asymptomatic women allowed to give birth, which is close to that of the public in general. However, due to the research venue and distribution facilities the prevalence of these positive tests varies. There are various methods for SARS-CoV-2 titration, including fast IgM-IgG antibody testing, chemiluminescence immunosorbent testing and enzyme-linked immunosorbent testing (ELISA). The ELISA procedure has 89 percent sensitivity and 91 percent accuracy, but it varies by day after the onset of symptoms<sup>25-28</sup>. Flu epidemics occur during the year and influenza pandemics also take place throughout summer. Sub-tropical regions such as Taiwan, Hong Kong, and Singapore are observed. Although the islands of Okinawa are situated in the southernmost region of Japan (26°N latitude), with a subtropical climate, various influenza epidemics occur in summer. In Okinawa Prefecture in the summer season, summer influenza was confirmed to be one of the leading causes of acute respiratory infections in children and adults<sup>29-34</sup>. We have also shown that influenza B viruses play a major role in summer epidemics in previous research. After the outbreak of SARS-CoV-2, which started in January 2020, in Japan, there is widespread support for measures to deter the transmittal of pathogens, such as gloves, hand washing, remote work, and large-scale cancellation. These interventions can also limit the spread of other infectious disorders such as seasonal influenza if they are successful. We assessed influenza activity weekly in the 2019-2020 season on the basis of this context. Two individual data sets were obtained from secondary sources from September 2019 to September 2020. The first data collection involved a national monitoring of the flu diagnosed by RAT and/or influenza-like symptoms. Japan's nationwide influenza screening is carried out in around 5000 sentinel health facilities throughout Japan, 55 of them in Okinawa Prefecture. Data were collected from the Infectious Diseases Weekly Reports issued by the Japanese National Institute for Infectious Diseases from these 55 sentinel healthcare institutions around Okinawa<sup>35-37</sup>.

**REFERENCES:**

1. Uprety P, Mathew J, Weinstein MP, Kirn TJ. Comparison of 4 molecular assays for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Diagn Microbiol Infect Dis*. 2021;99(2). doi:10.1016/j.diagmicrobio.2020.115196
2. Gupta D. Does mask use affect the quantitative severe acute respiratory syndrome coronavirus 2 load in the nasopharynx? *J Pediatr*. 2021;228:314. doi:10.1016/j.jpeds.2020.09.050
3. Collora JA, Liu R, Albrecht K, Ho Y-C. The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2. *Curr Opin HIV AIDS*. 2021;16(1):36-47. doi:10.1097/COH.0000000000000655
4. Savirón-Cornudella R, Villalba A, Zapardiel J, Andeyro-Garcia M, Esteban LM, Pérez-López FR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during labor and delivery. *Eur J Obstet Gynecol Reprod Biol*. 2021;256:400-404. doi:10.1016/j.ejogrb.2020.11.069
5. Banday AZ, Vignesh P. Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2. *J Pediatr*. 2021;228:315. doi:10.1016/j.jpeds.2020.09.054
6. Fujita J. Mycoplasma pneumoniae pneumonia and respiratory syncytial virus infection in Japan during the severe acute respiratory syndrome coronavirus 2 pandemic. *Respir Investig*. 2021;59(1):5-7. doi:10.1016/j.resinv.2020.11.002
7. Salazar E, Christensen PA, Graviss EA, et al. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. *Am J Pathol*. 2021;191(1):90-107. doi:10.1016/j.ajpath.2020.10.008
8. Mark EG, Golden WC, Gilmore MM, et al. Community-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Young Infants: A Systematic Review. *J Pediatr*. 2021;228:94-100.e3. doi:10.1016/j.jpeds.2020.09.008
9. Sunagawa S, Iha Y, Kinjo T, Nakamura K, Fujita J. Disappearance of summer

influenza in the Okinawa prefecture during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. *Respir Investig.* 2021;59(1):149-152. doi:10.1016/j.resinv.2020.10.010

10. Schwartz A, Yogev Y, Zilberman A, et al. Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vaginal swabs of women with acute SARS-CoV-2 infection: a prospective study. *BJOG An Int J Obstet Gynaecol.* 2021;128(1):97-100. doi:10.1111/1471-0528.16556
11. Lee B, Raszka W.V. J. You say potato, I say tomato: Reassessing severe acute respiratory syndrome coronavirus 2 viral loads in children. *J Pediatr.* 2021;228:316-317. doi:10.1016/j.jpeds.2020.09.048
12. Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. *J Rehabil Med.* 2020;52(5). doi:10.2340/16501977-2694
13. Giannantoni A, Rubilotta E, Balzarro M, Gubbiotti M. Continuing care for patients affected by urologic chronic pelvic pain in the era of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. *Neurourol Urodyn.* 2020. doi:10.1002/nau.24574
14. Malhotra Y, Rossberg MC, Bajaj K, Shtern A, Moore RM. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) Pneumonia. *Obstet Gynecol.* 2020;136(3):632-633. doi:10.1097/AOG.0000000000004073
15. Hu X, Gao J, Luo X, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) Pneumonia. *Obstet Gynecol.* 2020;136(1):65-67. doi:10.1097/AOG.0000000000003926
16. Purushothaman R, Sribiju MK, Joseph M, Radhakrishnan P. Coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome corona virus (SARS-CoV2) infections - An update. *J Indian Med Assoc.* 2020;118(3):20-27. <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090809875&partnerID=40&md5=56c44a78f6fb9847e01d0d35c3a7dd96>.

17. Afewerky HK. Pathology and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Exp Biol Med.* 2020;245(15):1299-1307. doi:10.1177/1535370220942126
18. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. *Sci Total Environ.* 2020;730. doi:10.1016/j.scitotenv.2020.138996
19. Schwartz DA, Morotti D, Beigi B, Moshfegh F, Zafaranloo N, Patanè L. Confirming vertical fetal infection with coronavirus disease 2019: Neonatal and pathology criteria for early onset and transplacental transmission of severe acute respiratory syndrome coronavirus 2 from infected pregnant mothers. *Arch Pathol Lab Med.* 2020;144(12):1451-1456. doi:10.5858/arpa.2020-0442-SA
20. Lombardi C, Roca E, Bigni B, Cottini M, Passalacqua G. Clinical course and outcomes of patients with asthma hospitalized for severe acute respiratory syndrome coronavirus 2 pneumonia: A single-center, retrospective study. *Ann Allergy, Asthma Immunol.* 2020;125(6):707-709. doi:10.1016/j.anai.2020.07.029
21. Warren N, Siskind D, Lie D. Electroconvulsive therapy during severe acute respiratory syndrome coronavirus 2 pandemic. *Aust N Z J Psychiatry.* 2020;54(12):1224. doi:10.1177/0004867420945777
22. Kanaujia R, Biswal M, Angrup A, Ray P. Inhale, then exhale: start afresh to diagnose Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by non-invasive face-mask sampling technique. *Clin Microbiol Infect.* 2020;26(12):1701-1702. doi:10.1016/j.cmi.2020.06.034
23. Lokken EM, Walker CL, Delaney S, et al. Clinical characteristics of 46 pregnant women with a severe acute respiratory syndrome coronavirus 2 infection in Washington State. *Am J Obstet Gynecol.* 2020;223(6):911.e1-911.e14. doi:10.1016/j.ajog.2020.05.031
24. Sadia A, Basra MAR. Therapeutic dilemma in the repression of severe acute respiratory syndrome coronavirus-2 proteome. *Drug Dev Res.* 2020;81(8):942-949. doi:10.1002/ddr.21710

25. Gomaa MR, Kandeil A, Mostafa A, et al. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors. *Front Microbiol.* 2020;11. doi:10.3389/fmicb.2020.596851
26. Deng J-L, Jiang Y-Q, Guo Y-K, Li H-L. Patients taking angiotensin-converting enzyme inhibitors/angiotensin II type I receptor blockers: higher risks of severe acute respiratory syndrome coronavirus 2 infection but milder clinical manifestations? *Chin Med J (Engl).* 2020;133(22):2650-2652. doi:10.1097/CM9.0000000000000996
27. Haddad G, Bellali S, Fontanini A, et al. Rapid Scanning Electron Microscopy Detection and Sequencing of Severe Acute Respiratory Syndrome Coronavirus 2 and Other Respiratory Viruses. *Front Microbiol.* 2020;11. doi:10.3389/fmicb.2020.596180
28. Luan B, Huynh T. In Silico Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2. *J Phys Chem Lett.* 2020;11(22):9781-9787. doi:10.1021/acs.jpcclett.0c02706
29. Albert CL, Carmona-Rubio AE, Weiss AJ, Procop GG, Starling RC, Rodriguez ER. The Enemy Within: Sudden-Onset Reversible Cardiogenic Shock With Biopsy-Proven Cardiac Myocyte Infection by Severe Acute Respiratory Syndrome Coronavirus 2. *Circulation.* 2020;142(19):1865-1870. doi:10.1161/CIRCULATIONAHA.120.050097
30. Lang P, Eichholz T, Bakchoul T, et al. Defibrotide for the Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2 Pediatric Patients. *J Pediatric Infect Dis Soc.* 2020;9(5):622-625. doi:10.1093/jpids/piaa117
31. Patel AB, Clifford A, Creaden J, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Point Prevalence Among Asymptomatic Hospitalized Children and Subsequent Healthcare Worker Evaluation. *J Pediatric Infect Dis Soc.* 2020;9(5):617-619. doi:10.1093/jpids/piaa102
32. Plotkin SA. Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2. *J Pediatric Infect Dis Soc.* 2020;9(5):517-518. doi:10.1093/jpids/piaa093
33. Schmidt E, Steinhagen K, Rupp J. Heavy Exposure of Children Aged 9-12 Years With Severe Acute Respiratory Syndrome Coronavirus 2 Did Not Lead to Infection. *J Pediatric Infect Dis Soc.* 2020;9(5):620-621. doi:10.1093/jpids/piaa116

34. Teherani MF, Kao CM, Camacho-Gonzalez A, et al. Burden of Illness in Households With Severe Acute Respiratory Syndrome Coronavirus 2-Infected Children. *J Pediatric Infect Dis Soc.* 2020;9(5):613-616. doi:10.1093/jpids/piaa097
35. Otto WR, Geoghegan S, Posch LC, et al. The Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Healthcare Network in the United States. *J Pediatric Infect Dis Soc.* 2020;9(5):523-529. doi:10.1093/jpids/piaa074
36. Wardell H, Campbell JI, VanderPluym C, Dixit A. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Febrile Neonates. *J Pediatric Infect Dis Soc.* 2020;9(5):630-635. doi:10.1093/jpids/piaa084
37. Bisogno G, Provenzi M, Zama D, et al. Clinical Characteristics and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Italian Pediatric Oncology Patients: A Study From the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica. *J Pediatric Infect Dis Soc.* 2020;9(5):530-534. doi:10.1093/jpids/piaa088